Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase 1/2a Study of BAL101553 Administered as Intravenous 48-hour Infusions in Adult Patients With Advanced Solid Tumors or Recurrent Glioblastoma

Next Previous
X
Search
Trial Profile

An Open-label Phase 1/2a Study of BAL101553 Administered as Intravenous 48-hour Infusions in Adult Patients With Advanced Solid Tumors or Recurrent Glioblastoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lisavanbulin (Primary) ; Lisavanbulin (Primary)
  • Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Glioblastoma; Ovarian cancer; Peritoneal cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Basilea Pharmaceutica

    • Most Recent Events

    • 16 Feb 2023 Results (from the Phase 2a portion of the study) assessing Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma published in the Investigational New Drugs
    • 15 Oct 2020 Status changed from active, no longer recruiting to completed.
    • 28 Jul 2020 According to a Basilea Pharmaceutica media release, final results from a phase 1 study will be published at European Society for Medical Oncology (ESMO) Virtual Congress 2020

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top